285 related articles for article (PubMed ID: 11830459)
21. Cytoreductive treatment patterns among US veterans with polycythemia vera.
Parasuraman S; Yu J; Paranagama D; Shrestha S; Wang L; Baser O; Scherber R
BMC Cancer; 2018 May; 18(1):528. PubMed ID: 29728092
[TBL] [Abstract][Full Text] [Related]
22. Polycythemia vera: a retrospective and reprise.
Berlin NI; Wasserman LR
J Lab Clin Med; 1997 Oct; 130(4):365-73. PubMed ID: 9358074
[TBL] [Abstract][Full Text] [Related]
23. Polycythemia and Thrombocytosis.
Parnes A; Ravi A
Prim Care; 2016 Dec; 43(4):589-605. PubMed ID: 27866579
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Spivak JL
Semin Hematol; 2003 Jan; 40(1 Suppl 1):1-5. PubMed ID: 12682874
[TBL] [Abstract][Full Text] [Related]
25. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
26. [Thrombocytosis].
Nigg C; Naumann UK; Käser L
Praxis (Bern 1994); 2008 Apr; 97(7):343-9; quiz 350-1. PubMed ID: 18548812
[No Abstract] [Full Text] [Related]
27. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic erythroapheresis: Experience in patients with polycythemia vera and secondary erythrocytosis.
Parra Salinas I; Recasens Flores V; Montañés MÁ; García-Erce JA
Med Clin (Barc); 2020 Jan; 154(1):16-19. PubMed ID: 30795904
[TBL] [Abstract][Full Text] [Related]
29. In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia.
Shih LY; Lee CT; See LC; Ou YC; Dunn P; Wang PN; Kuo MC; Wu JH
Eur J Clin Invest; 1998 Jul; 28(7):569-76. PubMed ID: 9726038
[TBL] [Abstract][Full Text] [Related]
30. Expertise-based management in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis.
Mossuz P; Girodon F; Donnard M; Latger-Cannard V; Dobo I; Boiret N; Lecron JC; Binquet C; Barro C; Hermouet S; Praloran V
Haematologica; 2004 Oct; 89(10):1194-8. PubMed ID: 15477203
[TBL] [Abstract][Full Text] [Related]
32. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
33. Diagnosing or ruling out polycythemia vera in patients with erythrocytosis.
Prchal JT
Clin Adv Hematol Oncol; 2019 Jan; 17(1):24-27. PubMed ID: 30843892
[No Abstract] [Full Text] [Related]
34. Polycythemia vera in a cat and management with hydroxyurea.
Evans LM; Caylor KB
J Am Anim Hosp Assoc; 1995; 31(5):434-8. PubMed ID: 8542363
[TBL] [Abstract][Full Text] [Related]
35. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C;
Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
[TBL] [Abstract][Full Text] [Related]
36. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.
Evers D; Kerkhoffs JL; Van Egmond L; Schipperus MR; Wijermans PW
J Clin Apher; 2014 Jun; 29(3):133-8. PubMed ID: 24130064
[TBL] [Abstract][Full Text] [Related]
37. Erythrocytosis due to presumed polycythemia vera.
Patell R; Theil K; Lichtin A
Cleve Clin J Med; 2016 Sep; 83(9):648-53. PubMed ID: 27618352
[No Abstract] [Full Text] [Related]
38. Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.
Rippel N; Tremblay D; Zubizarreta N; Podoltsev N; Gotlib J; Heaney M; Kuykendall A; O'Connell C; Shammo JM; Fleischman A; Kremyanskaya M; Hoffman R; Mesa R; Yacoub A; Mascarenhas J
Leuk Res; 2022 Aug; 119():106903. PubMed ID: 35717689
[TBL] [Abstract][Full Text] [Related]
39. The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias.
Thiele J; Kvasnicka HM; Zankovich R; Diehl V
Haematologica; 2001 Apr; 86(4):368-74. PubMed ID: 11325641
[TBL] [Abstract][Full Text] [Related]
40. Acute coronary disease in essential thrombocythemia and polycythemia vera.
Rossi C; Randi ML; Zerbinati P; Rinaldi V; Girolami A
J Intern Med; 1998 Jul; 244(1):49-53. PubMed ID: 9698024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
